Jeffrey D Kearns

6PUBLICATIONS
54CO-AUTHORS
Regenerative medicine (incl. stem cells)GlycoconjugatesAutoimmunityMolecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 11, 2026
Alternative posology for brolucizumab: a 6-week loading regimen is as effective as a 4-week regimen for the treatment of nAMD.

|Dec 17, 2024
QSP modeling of a transiently inactivating antibody-drug conjugate highlights benefit of short antibody half life.

Eshita Khera, Lekshmi Dharmarajan, Dominik Hainzl

|Feb 01, 2023
A root cause analysis to identify the mechanistic drivers of immunogenicity against the anti-VEGF biotherapeutic brolucizumab.

Jeffrey D Kearns, Paul Wassmann, Ufuk Olgac

|Feb 01, 2023
Anti-brolucizumab immune response as one prerequisite for rare retinal vasculitis/retinal vascular occlusion adverse events.

Anette C Karle, Matthias B Wrobel, Stephan Koepke

|Apr 11, 2022
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.

Andreas Weiss, Edwige Lorthiois, Louise Barys

|Oct 12, 2021
USP28 deletion and small-molecule inhibition destabilizes c-MYC and elicits regression of squamous cell lung carcinoma.

E Josue Ruiz, Adan Pinto-Fernandez, Andrew P Turnbull

Pageof 1

Frequent Collaborators

2 joint publications

Tina Rubic-Schneider

2 joint publications

Dominique Brees

2 joint publications

Pawan Mehan

2 joint publications

Amanda Littlewood-Evans